Bright Minds Biosciences Inc. (CSE:DRUG)
Canada · Delayed Price · Currency is CAD 92.09
-2.19 (-2.32%)
Sep 4, 2026, 1:51 PM EST
Bright Minds Biosciences Balance Sheet
Financials in millions CAD. Fiscal year is October - September.
Millions CAD. Fiscal year is Oct - Sep.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Cash & Equivalents | 307.83 | 82.91 | 5.72 | 6.75 | 11.63 | 19.76 |
Cash & Short-Term Investments | 307.83 | 82.91 | 5.72 | 6.75 | 11.63 | 19.76 |
Cash Growth | 499.03% | 1349.43% | -15.23% | -41.97% | -41.15% | 2370.22% |
Other Receivables | 1.1 | 0.41 | 0.05 | 0.04 | 0.16 | 0.11 |
Receivables | 1.1 | 0.41 | 0.05 | 0.04 | 0.16 | 0.11 |
Prepaid Expenses | 1.35 | 0.99 | 0.22 | 0.03 | 0.16 | 0.17 |
Total Current Assets | 310.28 | 84.31 | 5.99 | 6.81 | 11.95 | 20.04 |
Property, Plant & Equipment | 0.05 | 0.11 | 0.12 | 0.07 | 0.14 | - |
Other Intangible Assets | - | - | - | - | - | 0 |
Total Assets | 310.34 | 84.42 | 6.1 | 6.88 | 12.09 | 20.04 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Accounts Payable | 2.36 | 1.71 | 0.41 | 0.18 | 1.25 | 0.6 |
Accrued Expenses | 0.11 | 0.54 | 0.04 | 0.03 | 0.16 | 0.04 |
Current Portion of Leases | 0.07 | 0.08 | 0.08 | 0.07 | 0.07 | - |
Total Current Liabilities | 2.54 | 2.34 | 0.53 | 0.28 | 1.47 | 0.64 |
Long-Term Leases | - | 0.04 | 0.04 | - | 0.07 | - |
Total Liabilities | 2.54 | 2.38 | 0.57 | 0.28 | 1.54 | 0.64 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Common Stock | 365.98 | 123.25 | 35.42 | 33.91 | 32.24 | 27.08 |
Retained Earnings | -67 | -46.58 | -34.35 | -31.55 | -24.17 | -9.21 |
Comprehensive Income & Other | 8.82 | 5.37 | 4.46 | 4.23 | 2.48 | 1.53 |
Shareholders' Equity | 307.79 | 82.04 | 5.54 | 6.6 | 10.54 | 19.4 |
Total Liabilities & Equity | 310.34 | 84.42 | 6.1 | 6.88 | 12.09 | 20.04 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Total Debt | 0.07 | 0.13 | 0.12 | 0.07 | 0.14 | - |
Net Cash (Debt) | 307.76 | 82.78 | 5.6 | 6.67 | 11.49 | 19.76 |
Net Cash Growth | 500.55% | 1377.97% | -16.08% | -41.90% | -41.86% | 2370.22% |
Net Cash Per Share | 35.79 | 12.04 | 1.30 | 1.79 | 4.65 | 11.01 |
Filing Date Shares Outstanding | 9.86 | 7.79 | 6.99 | 4.46 | 3.74 | 2.37 |
Total Common Shares Outstanding | 9.86 | 7.64 | 4.52 | 3.77 | 3.52 | 2.37 |
Working Capital | 307.74 | 81.97 | 5.46 | 6.53 | 10.48 | 19.4 |
Book Value Per Share | 31.20 | 10.74 | 1.22 | 1.75 | 3.00 | 8.20 |
Tangible Book Value | 307.79 | 82.04 | 5.54 | 6.6 | 10.54 | 19.4 |
Tangible Book Value Per Share | 31.20 | 10.74 | 1.22 | 1.75 | 3.00 | 8.20 |